Applied Therapeutics (APLT) announced that the Company completed a meeting with the U.S. Food and Drug Administration to discuss the potential new drug application submission for govorestat for the treatment of Charcot-Marie-Tooth Sorbitol Dehydrogenase Deficiency in the third quarter of 2025. The Company is awaiting the receipt of official meeting minutes from the FDA in order to determine next steps. At this time, a path forward regarding a potential submission strategy for regulatory approval, including under the accelerated approval pathway, has not been determined. The Company remains committed to addressing the unmet needs of patients living with CMT-SORD.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on APLT:
- Applied Therapeutics up after details posted for confirmatory govorestat study
- Applied Therapeutics Announces New Equity Offering Agreement
- Strategic Positioning and Growth Potential: Joseph Schwartz’s Buy Rating on Applied Therapeutics
- Applied Therapeutics Granted Nasdaq Compliance Extension
- Applied Therapeutics Advances Pipeline Amid Financial Challenges